Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)58.79bn
- Net income in CHF10.62bn
- Incorporated1966
- Employees103.61k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttps://www.roche.com/
Mergers & acquisitions
Acquired company | ROG:SWX since announced | Transaction value |
---|---|---|
LumiraDx International Ltd | 10.33% | -- |
LumiraDx Group Ltd | 10.33% | 295.00m |
Carmot Therapeutics Inc | 11.64% | 3.10bn |
Holder | Shares | % Held |
---|---|---|
Canada Pension Plan Investment Boardas of 31 Mar 2024 | 1.92m | 1.80% |
APG Asset Management NVas of 31 Dec 2023 | 1.19m | 1.12% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 1.14m | 1.07% |
UBS Asset Management Switzerland AGas of 29 Aug 2024 | 780.34k | 0.73% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 752.01k | 0.71% |
Credit Suisse Asset Management (Schweiz) AGas of 31 Jul 2024 | 595.06k | 0.56% |
Z�rcher Kantonalbank (Investment Management)as of 31 Jul 2024 | 539.25k | 0.51% |
Geode Capital Management LLCas of 12 Sep 2024 | 309.84k | 0.29% |
Vontobel Asset Management AGas of 31 Aug 2024 | 239.94k | 0.23% |
BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 234.06k | 0.22% |